Treatment discontinuation, relative dose intensity at 12 months and actual total administered dose of S-1 (n = 97).
Treatment completion rate, which is the proportion of the patients who completed the administration of S-1 during the period (6 months, 9 months and 12 months) with 70% or more of RDI, was as follows: 69.4% for Arm A and 64.6% for Arm B at 6 months, 67.3% for Arm A and 56.3% for Arm B at 9 months, and 63.3% for Arm A and 45.8% for Arm B at 12 months. During the 1-year treatment course, 51.0% of the patients in Arm A and 16.7% of the patients in Arm B completed S-1 administration without a dose reduction or postponement (